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A B S T R A C T
Background
Cardiovascular disease accounts for more than half the number of deaths among dialysis patients. The role of HMG CoA reductase
inhibitors (statins) in the treatment of hyperlipidemia in dialysis patients is unclear and their safety has not been established.
Objectives
To assess the benefits and harms of statins in peritoneal dialysis (PD) and hemodialysis patients (HD).
Search strategy
We searched MEDLINE (1966-July 2003), EMBASE (1980-July 2003), the Cochrane Central Register of Controlled trials (CEN-
TRAL, in The Cochrane Library - issue 2, 2004), the Cochrane Renal Group’s specialized register (April 2004) and handsearched
reference lists of textbooks, articles and scientific proceedings.
Selection criteria
Randomized controlled trials (RCTs) and quasi-RCTs comparing statins with placebo, no treatment or other statins in dialysis patients.
Data collection and analysis
Two reviewers independently assessed trial quality and extracted data. Statistical analyses were performed using the random effects
model after testing for heterogeneity. The results were expressed as mean difference (MD) for continuous outcomes and risk ratio (RR)
for dichotomous outcomes with 95% confidence intervals (CI).
Main results
Six studies involving 357 participants were identified - three studies had both continuous ambulatory peritoneal dialysis (CAPD)
and HD participants, two included only HD participants and one study only included CAPD participants. Studies were all of short
duration and morbidity and mortality were not assessed. Average total cholesterol decreased significantly with statins compared to
placebo in all dialysis patients (MD -53.70 mg/dL (1.40 mmol/L), 95% CI -66.95 to -40.54). Similarly, average LDL cholesterol
decreased significantly with statins in comparison to placebo in all patients (MD -55.40 mg/dL (1.44 mmol/L), 95% CI -69.90 to -
40.90) as did average triglycerides (-33.72 mg/dL (0.37 mmol/L), 95% CI -54.16 to -13.28). There was a significant increase in average
HDL cholesterol levels (MD 4.84 mg/dL (0.13 mmol/L), 95% CI 0.28 to 9.40) with statins compared to placebo in HD but not in
CAPD patients. One trial compared statins to the hypolidemic agent probucol and found no significant differences between the two
treatment groups.
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Authors’ conclusions
Statins used for 12 weeks decreased cholesterol levels in dialysis patients similar to the general population. Included studies were of
short duration and therefore the efficacy of statins in decreasing the cardiovascular, cerebrovascular events and mortality rates is still
unclear. The safety of statins needs to be addressed in the current ongoing clinical trials.
P L A I N L A N G U A G E S U M M A R Y
Statins reduce total cholesterol and triglycerides in dialysis patients to a level similar to the general population
Dialysis patients are at high risk of heart disease and have high cholesterol levels. Statins have been shown to decrease cholesterol levels
and mortality in the general population. The aim of this review was to see if a similar effect could be shown in dialysis patients. This
review showed that statins decreased total cholesterol and triglyceride levels to a level similar to that seen in the general population.
Their long-term efficacy in decreasing the death rates and their side effect profile in dialysis patients still needs to be studied.
B A C K G R O U N D
By the end of year 2001, the United States had a prevalence of
1400 end-stage renal disease (ESRD) patients per million popu-
lation (total 300,000 patients), and 22.8 billion US dollars were
spent on treatment for dialysis and kidney transplant patients. The
prevalence of ESRD has increased throughout the world with an
increase in the number undergoing dialysis. For instance, from
1998-2001 there was an 85% increase in the prevalence in Thai-
land, 25% increase inPoland, and19% increase inRussia (USRDS
2003). Despite the large amount being spent on treating ESRD,
the number of deaths has increased from nearly 40,000 deaths/
year in 1992 to 70,000 deaths/year in 2000 in United States alone
(USRDS 2003). Cardiovascular disease accounts for more than
50% of these deaths (Wanner 1991; USRDS 2003). Dialysis pa-
tients with concomitant cardiovascular disease have a higher all-
cause mortality compared to the general population. Prevalence
of traditional cardiovascular risk factors like diabetes and hyper-
tension are also higher in the ESRD patients when compared to
the general population. In the study by Longenecker, based on
these traditional risk factors, the projected 5-year atherosclerotic
cardiovascular disease risk based on Framingham Risk Equation
was 13% in ESRD patients when compared to 6% in the general
population (Longenecker 2002). The incidence of acute myocar-
dial infarction among diabetic patients increases from75/1000 pa-
tient-year to 129/1000 patient-year by the fourth year. Also the use
of dialytic modalities varies significantly worldwide. Australia and
NewZealand have the highest percentage (40-50%) of patients on
continuous ambulatory peritoneal dialysis/continuous cyclic peri-
toneal dialysis (CAPD/CCPD) (ANZDATA 2003), whereas 80%
of US dialysis patients undergo hemodialysis (HD). This may also
influence the cardiovascular outcomes (USRDS 2003).
The primary lipid abnormality in both HD and CAPD patients
is hypertriglyceridemia. This is due to the decreased activity of a
lipoprotein lipase caused by the presence of a lipoprotein lipase
inhibitor and reduction in apo-C-II activity (Senti 1992). There
is also a mildly elevated LDL cholesterol level with a marked pre-
dominance of highly atherogenic small dense LDL particles in
these patients. Low HDL cholesterol with a resultant increase in
the LDL/HDL ratio and elevated lipoprotein (a) contributes to
the atherosclerotic complications in HD patients (Cheung 1993;
Cressman 1992). CAPD patients havemore atherogenic lipid pro-
file than HD patients. CAPD patients have significantly lower
HDL cholesterol, increased LDL/HDL ratio, and have higher
lipoprotein (a) levels due to the lose of large amounts of proteins in
the dialysate fluid (Kronenberg 1995; Siamopoulos 1995). Also,
CAPD patients have higher total cholesterol due to absorption of
glucose from the dialysate solution contributing to the enhanced
atherosclerosis in these patients (Appel 1991).
Numerous treatment modalities have been tried in the dialysis
population includingdietary therapy, high-fluxmembranes inHD
patients and hypolipidemic drug therapy. Dietary modification
is the initial treatment for the hypercholesterolemic patients in
the general population and has also been shown to be effective
in reducing the cholesterol levels in dialysis patients. However
dietarymanipulation in these patients may be difficult as they have
complex, pre-existing dietary requirements related to dialysis. For
patients on HD, reducing the total fat intake to less than 40% of
total energy is difficult as it may result in decreased overall energy
intake. Compliance is also a major issue. Thus dietary therapy
alone is usually insufficient to achieve near normal lipid levels,
necessitating pharmacotherapy (Saltissi 2001). The use of high-
flux membranes in HD patients improves the lipid abnormalities
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comparable to the extent with dietary treatment but not to the
extent as hypolipidemic drugs (Blankestijn 1995; House 1998).
HMG CoA reductase inhibitors (statins) have been shown to be
effective in both primary and secondary prevention of cardiovas-
cular events in high-risk patients in the general population (NCEP
2001). They reduce newly synthesized serum cholesterol ester
transfer activity, lecithin, cholesterol acetyltransferase (LCAT) ac-
tivity, and serum LDL, IDL, lipoprotein, and apolipoprotein con-
centrations and may increase HDL cholesterol levels (Wanner
1991; PERFECT Study 1997). A recent cohort study (United
States Renal Data System Morbidity and Mortality Study wave
2 (USRDS DMMS-2)), concluded that statin use was associated
with reduced cardiovascular and total deaths in dialysis patients
(Seliger 2002). Numerous clinical trials have analyzed their sa-
fety and efficacy in reducing the serum cholesterol to or near to
acceptable levels in HD and CAPD patients (Harris 2002; Li
1993; Nishikawa 1999; Saltissi 2002; Wanner 1991). A literature
search revealed a meta-analysis conducted in 1995 that analyzed
the efficacy of various treatment modalities including statins in
pre-dialysis, dialysis and transplant patients (Massy 1995). This
meta-analysis included non-randomized controlled trials (RCTs)
and included studies using different cut-off values for the serum
cholesterol levels, and many were undertaken before the introduc-
tion of Adult Treatment Panel III guidelines for hyperlipidemia
(NCEP 2001). Most of the RCTs analyzing the efficacy of statins
in dialysis patients were done in the past 10 years. In addition,
the impact on mortality and safety were not assessed. Therefore,
a systematic review was needed to analyze whether statins help
to decrease cholesterol levels in dialysis patients and decrease the
cardiovascular, cerebrovascular events and mortality rates in these
patients without significant adverse effects.
O B J E C T I V E S
This review aimed to look at the benefits (reduction in the choles-
terol levels, all cause mortality, cardiovascular and cerebrovascular,
mortality, cardiovascular and cerebrovascular events) and harms
(elevated liver enzymes, rhabdomyolysis) of statins in dialysis pa-
tients.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs and quasi-RCTs of at least 12 weeks duration looking at
benefits and harms of statins in dialysis patients. The first period
of randomized crossover studies was to be included.
Types of participants
Inclusion criteria
All diabetic and non-diabetic ESRD patients, more than 18 years
of age, undergoing dialysis (HD or peritoneal dialysis (PD)) for at
least six months regardless of their baseline cholesterol level.
Exclusion criteria
Patients with active liver disease or impaired liver function, ele-
vated creatine phosphokinase, on multiple lipid lowering agents
and on other medications that might interfere with statins.
Types of interventions
Studies analyzing the use of statins in dialysis patients compared
to a placebo or no drug treatment for at least three months (end
of treatment values), studies comparing statins and other lipid
lowering agents for at least threemonths and the studies comparing
different statins in dialysis patients were considered for inclusion.
Types of outcome measures
1. Effect on serum total cholesterol, LDL cholesterol, HDL
cholesterol, triglyceride levels and liver function tests (LFT).
2. All cause, cardiovascular, and cerebrovascular mortality.
3. Cardiovascular and cerebrovascular event rates (non-fatal
myocardial infarction (MI) including revascularization rates,
stroke).
4. Adverse events: elevated liver enzymes, creatine
phosphokinase levels or rhabdomyolysis, withdrawal rates.
Search methods for identification of studies
Electronic searches
Relevant trials were obtained from the following sources (see ad-
ditional Table 1 - Electronic search strategies):
1. The Cochrane Renal Group’s specialized register of RCTs
for any “New” records not yet incorporated in the specialized
register (last search April 2004)
2. Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library, Issue 2, 2004
3. MEDLINE and Pre-MEDLINE 1966 - July 2003 - to
ensure all trials have been identified.
4. EMBASE 1980 - July 2003 - to ensure all trials have been
identified
Thiswas combinedwith theCochrane highly sensitive search strat-
egy for identifying RCTs in MEDLINE (Dickersin 1994), and
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a similar strategy for EMBASE (Lefebvre 1996). Please see the
Cochrane Renal Group Module for details of these strategies.
Searching other resources
1. Reference lists of nephrology textbooks, review articles and
relevant trials.
2. Reference lists of abstracts from nephrology scientific
meetings (ASN, EDTA, World Congress of Nephrology, Asian
Pacific Congress of Nephrology).
Data collection and analysis
The reviewers (SN, RS) screened all abstracts obtained through
the MEDLINE, EMBASE, Renal Group Specialized register and
CENTRAL independently. Studies relevant to dialysis and hyper-
cholesterolemic drugs were identified. Studies that might include
relevant data or information on trials involving HMG Co-A re-
ductase inhibitors were retained initially. Full texts of these studies
were obtained as needed to determine whether the studies were
eligible for the review. Studies published in non-English language
journals were translated before assessment for inclusion. Reviewers
(SN, RS) independently extracted data from the eligible studies
using standard data extraction forms.Wheremore than one publi-
cation of one trial existed, only the publication with themost com-
plete data was included. Any further information required from
the original author was requested and any relevant information
obtained was included in the review. Disagreements among the
reviewers (SN, RS) were resolved in consultation with Cochrane
Renal Group editorial office.
Study quality
The quality of studies included in the review was assessed indepen-
dently by (SN) and (RS) without blinding to authorship or journal
using the checklist developed for the Cochrane Renal Group. The
quality items assessed were allocation concealment, intention-to-
treat analysis, completeness to follow-up and blinding of investi-
gators, participants and outcome assessors.
Quality checklist
Allocation concealment
• Adequate (A): Randomization method described that would
not allow investigator/participant to know or influence
intervention group before eligible participant entered in the
study
• Unclear (B): Randomization stated but no information on
method used is available
• Inadequate (C): Method of randomisation used such as
alternate medical record numbers or unsealed envelopes; any
information in the study that indicated that investigators or
participants could influence intervention group
Blinding
• Blinding of investigators: Yes/No/not stated
• Blinding of participants: Yes/No/not stated
• Blinding of outcome assessor: Yes/No/not stated
• Blinding of data analysis: Yes/No/not stated
The above are considered not blinded if the treatment group can
be identified in >20% of participants because of the side effects of
treatment.
Intention-to-treat analysis
• Yes: Specifically reported by authors that intention-to-treat
analysis was undertaken and this was confirmed on study
assessment.
• No: Not reported and lack of intention-to-treat analysis
confirmed on study assessment. (Patients who were randomised
were not included in the analysis because they did not receive the
study intervention, they withdrew from the study or were not
included because of protocol violation)
• Not stated
Completeness to follow-up
Percentage of participants excluded or lost to follow-up.
Statistical assessment
The studies were combined quantitatively when it was appropri-
ate.Meta-analyses were performed to analyze the efficacy of statins
in all dialysis patients, and HD and PD patients separately. Sep-
arate analyses were done for total cholesterol, LDL cholesterol,
HDL cholesterol, and triglyceride levels. For dichotomous out-
comes (all-cause mortality, cardiovascular or cerebrovascular mor-
tality), results were to be expressed as risk ratio (RR) with 95%
confidence intervals (CI). Where continuous scales of measure-
ment were used to assess the effects of treatment (total cholesterol,
LDL cholesterol, HDL cholesterol, triglycerides), the mean dif-
ference (MD) by comparing the end of treatment values was used.
Data was pooled using the random effects model. Heterogeneity
among the included trials was analyzed using chi-square testing
and the I² test. A value of >50% in I² testing indicates substantial
heterogeneity among the included studies.
Subgroup analysis was planned to explore the possible sources of
heterogeneity. It was planned to assess the efficacy of statins in de-
creasing cholesterol at different doses and the incidence of adverse
events at various doses. We also planned to analyze the efficacy of
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statins at different treatment duration (e.g. at 12 weeks, 6 months,
1 year) that might cause heterogeneity, however these could not
be done as there were only a few studies. Adverse effects, especially
elevated LFT and withdrawal rates were tabulated and assessed
with descriptive techniques, as they were likely to be different for
the various agents used. Where possible, the risk ratio (RR) with
95% CI was calculated for elevated LFT and withdrawal rates,
either compared to no treatment or to another agent.
It was planned that if sufficient RCTs were identified, an attempt
would be made to examine for publication bias using a funnel plot
(Egger 1997).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
The combined search of MEDLINE, EMBASE, the Cochrane
Renal Group’s specialized register and CENTRAL identified 81
articles of which 66 were excluded. Seven abstracts were identified
from scientific proceedings and five were excluded. The major
reasons for exclusion were:
1. studies were not randomized,
2. RCTs of less than 12 weeks duration,
3. RCTs with irrelevant outcomes to this analysis.
Seventeen relevant articles were identified after reviewing the ab-
stracts (Akcicek 1996; Diepeveen 2001; Fiorini 1994; Harris
2002; Hufnagel 2000; Li 1992; Lins 2002; Nishizawa 1995;
Nishikawa 1999; Malyszko 2002; PERFECT Study 1997 (2 re-
ports); Saltissi 2002; Tani 1998; Wanner 1991; Wanner 1992;
Zhu 2000). Full text assessment of these 17 articles (along with
information from the authors of abstracts of scientific proceed-
ings) resulted in six eligible studies (Diepeveen 2001; Fiorini 1994;
Harris 2002; Lins 2002; PERFECT Study 1997; Saltissi 2002).
A total of six studies were finally included in this meta-analysis
(Figure 1).
Figure 1.
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Of these six included studies, three studies included patients on
both HD and PD (Diepeveen 2001; PERFECT Study 1997;
Saltissi 2002). One study included PD patients alone (Harris
2002) and two studies included HD patients alone (Fiorini 1994;
Lins 2002). All six trials varied in size, type of statin, duration of
treatment and drug dosage. In one trial the participants had dietary
intervention prior to enrolment in the study (Saltissi 2002) and
only one trial included patients with normal cholesterol (Fiorini
1994).
Authors of two published studies and three abstracts were con-
tacted for additional information and three authors replied to our
requests. All the studies were designed to analyze the decrease in
the lipid parameters with statins. None of these studies looked
at the overall mortality, cardiovascular and cerebrovascular events
and mortality that we intended to analyze.
Risk of bias in included studies
Trial quality varied among the studies (Additional Table 2 -Quality
assessment of included trials)
Allocation concealment
Method of randomisation and allocation concealment was ade-
quate in one study (PERFECT Study 1997) and unclear in the
remaining five.
Blinding
One study blinded both the investigators and participants (
PERFECT Study 1997). It is unclear if the other five studies
blinded the participants, investigators or outcome assessors.
Intention-to-treat analysis
Three studies were analyzed on an intention-to-treat basis (Harris
2002; PERFECT Study 1997; Saltissi 2002).
Completeness of follow-up
There were no dropouts or loss to follow-up in one study (Fiorini
1994) and this was not mentioned in two (Diepeveen 2001; Lins
2002;). There was a 15.9% (13/82) drop out rate in the statin
group and 11.7% (11/94) dropout rate in the placebo group in
the study by Harris 2002. Similarly, Saltissi 2002 had a 15.7%
drop out rate in both statin and placebo group. PERFECT Study
1997 had a drop out rate of 26% in the statin group versus 17%
in the placebo group.
Effects of interventions
Statins versus placebo
Dialysis patients - combined hemodialysis and peritoneal
dialysis (five studies)
Total cholesterol
Average total cholesterol decreased significantly with statins com-
pared to placebo and there was significant heterogeneity between
these trials (Analysis 1.1: five studies, 357 patients; MDAnalysis
. -53.74 mg/dL (1.40 mmol/L), 95% CI -66.95 to -40.54; χ² =
13.34, P = 0.04, I² = 55.0%).
LDL cholesterol
There was a significant decrease in average LDL cholesterol level
with statins when compared to placebo and there was significant
heterogeneity between these trials (Analysis 1.2: five studies, 357
patients; MDAnalysis . -55.40 mg/dL (1.44 mmol/L), 95% CI -
69.90 to -40.90; χ² = 21.32, P 0.002, I² = 71.9%).
HDL cholesterol
The average HDL cholesterol did not increase significantly with
statins in comparison to placebo and there was no significant het-
erogeneity between these trials (Analysis 1.3: five studies, 357 pa-
tients; MDAnalysis . 2.19 mg/dL (0.06 mmol/L), 95% CI -0.30
to 4.69; χ² = 3.92, P = 0.69, I² = 0%).
Triglycerides
Average triglycerides decreased significantly with statins in com-
parison to placebo and there was no significant heterogeneity be-
tween these trials (Analysis 1.4:, five studies, 357 patients; MD-
Analysis . -33.72mg/dL (0.37mmol/L), 95%CI -54.16 to -13.28;
χ² = 3.92, P = 0.69, I² = 0%).
Hemodialysis patients (three studies)
Total cholesterol
Average total cholesterol decreased significantly with statins com-
pared to placebo and there was no significant heterogeneity be-
tween these trials (Analysis 1.1.2: three studies, 86 patients; MD-
Analysis . -53.44mg/dL (1.38mmol/L), 95%CI -77.90 to -28.98;
χ² = 4.04, P = 0.13, I² = 50.5%).
LDL cholesterol
There was a significant decrease in average LDL cholesterol level
with statins compared to placebo and there was no significant
heterogeneity between these trials (Analysis 1.2.2: three studies,
86 patients; MDAnalysis . -47.29 mg/dL (1.22 mmol/L), 95%CI
-62.01 to -32.57, χ² = 1.18, P = 0.56, I² = 0%).
HDL cholesterol
The averageHDLcholesterol increased significantlywith statins in
comparison to placebo and there was no significant heterogeneity
between these trials (Analysis 1.3.2: three studies, 86 patients;
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MDAnalysis . 4.84 mg/dL (0.13 mmol/L), 95% CI 0.28 to 9.40;
χ² = 1.36, P = 0.51 I² = 0%).
Triglycerides
Average triglycerides decreased with statins in comparison to
placebo, however this was not significant (Analysis 1.4.2: three
studies, 86 patients; MDAnalysis . -32.48 mg/dL (0.32 mmol/L),
95% CI -66.73 to 1.76; χ² = 0.88, P = 0.64, I² = 0%).
Peritoneal dialysis patients (three studies - CAPD patients)
Total cholesterol
Average total cholesterol decreased significantly with statins com-
pared to placebo and there was significant heterogeneity between
these trials (Analysis 1.1.1: three studies,164 patients; MDAnaly-
sis . -64.16 mg/dL (1.66 mmol/L), 95% CI -86.81 to -41.51; χ²
= 5.16, P = 0.08, I² = 61.2%).
LDL cholesterol
There was a significant decrease in average LDL cholesterol level
with statins in comparison to placebo and there was significant
heterogeneity between these trials (Analysis 1.2.1: three studies,
164 patients; MDAnalysis . -76.44 mg/dL (1.98 mmol/L), 95%
CI -106.12 to -46.77; χ² = 10.49, P = 0.005, I² = 80.9%).
HDL cholesterol
The average HDL cholesterol did not increase significantly with
statins in comparison to placebo and there was no significant het-
erogeneity between these trials (Analysis 1.3.1: three studies, 164
patients; MDAnalysis . -1.17 mg/dL (0.03 mmol/L), 95% CI -
9.21 to 6.87; χ² = 3.68, P = 0.16, I² = 45.7%).
Triglycerides
Average triglycerides decreased significantly with statins in com-
parison to placebo and there was no significant heterogeneity be-
tween these trials (Analysis 1.4.1: three studies, 164 patients; MD-
Analysis . -44.11mg/dL (0.49mmol/L), 95%CI -75.32 to -12.90;
χ² = 1.92, P = 0.38, I² = 0%).
Statins verus other hypolipidemic agents
We found only one study comparing statins with other hypolipi-
demic agents (Fiorini 1994). This study showed no significant dif-
ference in total cholesterol, LDL cholesterol, HDL cholesterol or
triglycerides with the use of statins compared to probucol.
Adverse events
Withdrawal rates and elevated LFT were the only adverse events
reported (Harris 2002; PERFECT Study 1997; Saltissi 2002).
There were no significant differences in withdrawal rate (Analysis
3.1) or elevated LFT (Analysis 3.2) for CAPD or HD patients.
Quality of life
None of the studies reported quality of life measures.
Publication bias
We were not able to evaluate publication bias with a funnel plot
or other methods due to the small number of trials.
D I S C U S S I O N
We found that statins decreased average total cholesterol by 54
mg/dL (1.40mmol/L) in dialysis patients (CAPD 64mg/dL (1.66
mmol/L); HD 53 mg/dL (1.38 mmol/L)). LDL cholesterol was
similarly reduced by an average of 55 mg/dL (1.44 mmol/L)
(CAPD 76 mg/dL (1.98 mmol/L); HD 47 mg/dL (1.22 mmol/
L)). In dialysis patients triglycerides were significantly decreased by
34 mg/dL (0.37 mmol/L). This decrease was significant in CAPD
patients (CAPD44mg/dL (0.49mmol/L) but not inHDpatients.
There was significant increase in HDL cholesterol in HD patients
(4.84 mg/dL (0.13 mmol/L) but not in CAPD patients (1.17 mg/
dL (0.03 mmol/L). None of these studies assessed the role of statin
potency to decrease cardiovascular events, cerebrovascular events
andmortality which are the important outcomes, and ones we had
intended to analyze. Also the safety profile of statins in dialysis
patients is not well studied. Statins are widely used in the primary
and secondary prevention of coronary artery disease in the general
population and have been shown to decrease total cholesterol by
an average 40-60 mg/dL and LDL cholesterol by 35-50 mg/dL
with an increase of HDL by 2-5 mg/dL in the general population
(Downs 1998; Shepherd 1995). This decrease in total cholesterol
and LDL cholesterol resulted in a reduction of cardiovascular and
cerebrovascular events (4S study 1994; Downs 1998; LIPID study
1998). Thus this review supports the widely held belief that statins
would have a similar effect in decreasing total cholesterol levels
in dialysis patients, even though their long-term utility is still not
established.
Dosing of statins in chronic kidney disease and the general popula-
tion is similar, as they do not undergo renal excretion (Appel 2002;
Stern 1997). Thus, reduction of total cholesterol levels in patients
on dialysis may be similar to those of non-uremic patients. Hyper-
triglyceridemia is the major lipid abnormality in ESRD patients
and it increases the highly atherogenic, small, dense LDL parti-
cles thereby increasing the cardiovascular risk (Quaschning 1999).
Hypertriglyceridemia has also been shown to be a significant risk
factor for coronary artery disease. Our meta-analysis showed that
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statins produced significant reduction in triglyceride levels in dial-
ysis patients in general, and CAPD patients in particular. Thus
statins may have an additional benefit in those patients on CAPD.
In addition, elevated LDL and total cholesterol levels, low HDL
cholesterol and the resultant increased LDL/HDL ratio are other
contributing factors to the atherosclerotic complications in dial-
ysis patients (Cheung 1993; Cressman 1992). This meta-analysis
showed that statins significantly reduced LDL cholesterol in both
HD and CAPD patients. The effect on HDL was only statistically
significant in HD patients. Whether the decrease in triglycerides,
total cholesterol, and LDL cholesterol persisted, and whether the
decrease translated into reduced morbidity and mortality remains
unanswered.
Exact decreases in cholesterol levels with different doses could not
be assessed as the studies were of different duration and used dif-
ferent statins with different dosage. However this meta-analysis
showed a statistically significant decrease in cholesterol level with
the use of statins for 12 weeks in both CAPD and HD patients. A
low baseline cholesterol level in the presence of low albumin has
been described as a predictor of high cardiovascular mortality. Hy-
percholesterolemia in normo-albuminemic patients have higher
cardiovascular mortality rates, similar to the general population
(Iseki 2002; Liu 2004). We were not able to analyze the efficacy of
statins separately in normo-albuminemic and hypoalbuminemic
patients due to insufficient data.
Linking evidence to practice: Various studies have shown that LDL
cholesterol levels remain >130 mg/dL in >50% of the dialysis pop-
ulation and are considered to be having coronary artery disease
equivalents. However statins were prescribed to only 10-20% of
patients (Harris 2002; Longenecker 2002; Seliger 2002). Most of
these studies were done prior to 2001. The prescribing pattern of
statins has changed and the rates might have increased in the past
few years. Based on a data analysis fromUSRDS, the use of statins
decreased cardiovascular-specific death and total mortality in dial-
ysis patients (Seliger 2002).NKF-KDOQI guideline recommends
treatment with statins in dialysis patients with LDL >100 mg/dL
after therapeutic lifestyle changes and dietmodification (K/DOQI
2003). These guidelines are based on the best available evidence
about statins in the general population, a few retrospective studies
and data analysis in dialysis patients due to the lack of RCTs in the
dialysis population. The pleiotropic effects of statins have been es-
tablished and shown to play a major role in reducing mortality in
the general population (Farmer 2000). Thus the role of statins in
hyperlipdemic patients has been justified in dialysis patients and
the use of statins is increasing. Ongoing studies (4D Study 2004;
AURORA Study 2003; HARP Study 1999; SHARP Study 2003)
are designed to analyze the efficacy of statins in decreasing the
mortality in dialysis patients. Results of these studies are expected
in next few years and might give a better understanding to the role
of statins in this population, including their safety.
Strengths and limitations: This is the first systematic review ana-
lyzing the efficacy of statins in dialysis patients. Only RCTs were
included to increase the quality of evidence. The sample size of
included studies was small and the studies were of short duration.
Adverse event rates were not reported in all studies and a reason-
able analysis could not be done. Efficacy of various doses of statins
is unclear. The results should be interpreted in the light of these
limitations.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Statins decreased cholesterol levels in dialysis patients to levels sim-
ilar to those seen in the general population when treated for 12
weeks. The impact of this decrease on mortality rates amongst pa-
tients on dialysis is unclear which is key to the treatment of hyper-
lipidemia in these patients. Safety of statins in these patients could
not be determined This meta-analysis validates the use of statins
in hyperlipidemic dialysis patients with appropriate monitoring
of adverse effects until the results of ongoing RCTs are available
and can be incorporated into this review.
Implications for research
Well-designed multi-center RCTs are needed to analyze the effi-
cacy of statins in decreasing mortality and morbidity (all-cause,
cardiovascular, cerebrovascular) rather than just looking at the effi-
cacy in decreasing cholesterol levels. These studies should include
patients with and without cardiovascular or cerebrovascular dis-
ease, and with and without elevated cholesterol levels and analyze
the benefits of statins. Both HD and PD patients should be in-
cluded and analyzed in subgroups. Studies should be of longer du-
ration and should address the safety of statins in dialysis patients.
These studies should also try to analyze the cut-off level for LDL
cholesterol levels that might decrease mortality rates in dialysis
patients. This might be different for dialysis patients from general
population.
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Method of allocation: Unclear
Withdrawals: Unclear
Intention to treat: Unknown
Publication Type: Abstract in scientific meeting
Participants Number randomised: 23 HD and 25 PD patients








D: Placebo + Placebo.
Study Duration: 12 weeks
Outcomes 1 .Lipid parameters (TC, LDL, HDL, TG)
Notes Study included 4 arms and we compared C and D.(see interventions)
Risk of bias
Item Authors’ judgement Description




Method of randomisation: Unclear
intention to treat: unclear
Participants Number randomised:12
Age:Exp 64(14)yr; Placebo 62.8(10)
Sex: Both
Inclusion criteria: Patients on HD for at least 6 months,hypertriglyceridemia,normal or increased choles-
terol’s levels, normal or reduced HDL level:LDL/HDL ratio was raised.
Exclusion criteria: Diabets Mellitus,liver failure,therapy with beta-blockers,thiazides,androgens and lipid
lowering drugs
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Fiorini 1994 (Continued)
Interventions Exp: Simvastatin 20mg/day
Control: Probucol
Duration:6 months
Outcomes 1. Lipid parameters (TC, TG, LDL, HDL, LDL/HDL, Apo-A)
2. Liver function tests, CK levels
Notes
Risk of bias
Item Authors’ judgement Description




Method of allocation: Unclear
Withdrawals: Numbers and reason described
Intention to treat: yes
Participants Number Randomised:116 CAPD patients. (Exp-82, Placebo-95)
Age: Exp:56.7(15.4) yr; Placebo: 57.5(13.5) yr
Sex: Both
Inclusion Criteria: CAPD or APD for at least 3 months, TC>200mg/dl, LDL >135 mg/dl,dyslipidemia
uncontrolled by other lipid lowering therapy for at least 4 weeks.
Exclusion criteria: Active liver disease or Increased ALT or AST (>3 X ULN), concurrent therapy with
immunosuppressants, uncontrolled DM, patient receiving other lipid lowering agents, patients with his-
tory of PTCA, CABG within 3 months, alcohol abuse, clinical evidence of inflammatory muscle disease
and total cholesterol >310 mg/dL)
Interventions Exp: Atorvastatin 10mg and dose increased to 40 mg as needed to achieve LDL<135 mg/dL
Duration:16 weeks
Outcomes 1.Lipid parameters (TC, LDL, HDL, TG)
2.Clinical adverse events along with ALT, AST, CK monitoring
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Method of randomisation: Unclear
Withdrawals: Not reported
Intention to Treat: Unknown
Publication Type: Abstract in scientific meeting.
Participants Number Randomised: 42
Hemodialysis patients (Exp 23, Placebo-19)
Age: Exp 63.8 (12.3) yr; Placebo 65.2 (9.3) yr
Sex: Both
Inclusion Criteria: Total cholesterol >210 mg/dl and total TG >500 mg/dl
Exclusion criteria: Not mentioned
Interventions Exp: Atorvastatin forced 4-weekly titration of 10 to 20 and to 40 mg once daily.
Study duration: 12 weeks.
Outcomes 1. Lipid parameters (TC, TG, LDL, HDL) and apoproteins (A-I, A-II,B,E,CIII)
2. Adverse events (Specific details unknown)
Notes Study awaiting publication.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
PERFECT Study 1997
Methods Country: New Zealand
Randomised: 4 Factorial design
Method of allocation: code maintained by a person separate to the study
Blinding: double blind (patient and investigator)
Withdrawals: not stated
Intention to treat: Yes
Follow-up: 6 months
Publication Type: Journal article
Participants Combined HD and CAPD patients
Age: mean (± SD) 50 ± 15 y
Sex (M/F): 32/21
Inclusion criteria: Not stated
Exclusion criteria: Definite indication for statin or ACEi, known allergy to either drug, planned transplant
from LRD in next 12months, congestive heart failure, severe valve disease, supine systolic BP , 100mmHg
or significant postural hypotension, uncontrolled hypertension, hepatitis B or C positive, AST or ALT
> twice upper limit or normal, treatment with cyclosporin or a fibrate, life threatening illness or serious
debilitating disease other than CRF
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PERFECT Study 1997 (Continued)
Interventions Statin group - Simvastatin plus placebo enalapril (b)
n = 24
10 mg daily
Placebo group - Placebo simvastatin plus placebo enalapril (d)
n = 29
Outcomes 1.Lipid parameters (TC, LDL, HDL, TG)
Notes Study had four arms
a) Simvastatin plus enalapril
b) Simvastatin plus placebo enalapril
c) Placebo simvastatin plus enalapril
d) Placebo simvastatin plus placebo enalapril
Risk of bias
Item Authors’ judgement Description




Method of allocation: Unclear
Withdrawals: Number and reason described
Intention to treat: Yes
Participants Number randomised: 34 HD and 23 CAPD patients
HD: 22 - Exp drug and 12 Placebo
CAPD:16-Exp drug and 7-Placebo
Age: HD: Exp 59.5 (13.9)yr ;Placebo 62.8 (9.6) yr
CAPD: Exp 55.3 (13.3)yr; Placebo 61.0 (7.6) yr
Sex: Both
Inclusion Criteria: HD or CAPD for 9 months, Non-HDL >135mg/dl, LDL >116mg/dl, TG <600mg/
dl
Exclusion Criteria: Impaired hepatic function, elevated CPK, Myocardial insufficiency, uncontrolled di-
abetes mellitus,active infection, malignancy and treatment with other lipid lowering agents
Interventions 117 patients who met inclusion criteria were treated with Australian National Heart foundation lipid
lowering diet for 6 weeks. Patients who did not acchieve the desired LDL, TC were randomised in 2:1
fashion.
EXP: Simvastatin 5mg and dose was increased to 20 mg as needed to achieve Non-HDL <135 mg/dL
Duration:24 weeks
Outcomes 1. Lipid parameters (TC, LDL, HDL, TG, Lp(a),Apo A1 ).
2. Clinical adverse experiences along with ALT, AST and CK monitoring
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Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Akcicek 1996 Prospective cohort study
Hufnagel 2000 Prospective cohort study
Li 1992 Study duration was less than 12 weeks
Malyszko 2002 Prospective cohort study
Nishikawa 1999 Prospective cohort study
Nishizawa 1995 Prospective cohort study
Tani 1998 Prospective cohort study
Wanner 1991 Prospective cohort study
Wanner 1992 Prospective cohort study
Zhu 2000 Prospective cohort study
Characteristics of ongoing studies [ordered by study ID]
4D Study 2004
Trial name or title The Determination of cardiovascular endpoints in niDDm Dialysis patients study (4D Study)
Methods
Participants Patients on hemodialysis for less than 2 years and with diabetes
Interventions Atrovastatin 20 mg/day vs placebo
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4D Study 2004 (Continued)
Outcomes Primary outcome:Cardiovascular mortality
Secondary outcome:Allcause mortality,non-fatal cardiovascular events,fatal and non-fatal cerbrovascular dis-
ease,and the mean percentage change in lipid profile from baseline
Starting date 2004






Trial name or title AURORA: A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of
survival and cardiovascular events
Methods
Participants 2700 subjects will be randomised at approx 190 sites from Australia, Canada and Europe. It is anticipated that
300 patients will be recruited from 20 centres within the UK. It is expected that each centre will randomise
between 10-20 patients. Subjects will be selected from Secondary care centres, according to the inclusion and
exclusion criteria. This may involve the Investigator/Research Nurse at the site screening medical records to
identify potentially suitable subjects. Potentially suitable subjects may also be identified via routine clinics at
the hospital
Interventions Subjects will be randomly assigned to either rosuvastatin treatment (10 mg/day) or placebo with a 1:1
randomisation ratio (ie, 150 placebo controls)
Outcomes (1) time from randomisation to death from any cause
(2) time from randomisation or major cardiovascular event (non-fatal stroke, non-fatal myocardial infarction
or cardiovascular death)
Starting date May 2003
Contact information Dr Alan Jardine





Telephone: 0141 211 2000
Fax: 0141 339 2800
Email: a.g.jardine@clinmed.gla.ac.uk
Notes
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HARP Study 1999
Trial name or title HARP - Heart and Renal Protection pilot study
Methods A randomised, double-blind 2x2 factorial study assessing the safety and biochemical efficacy of simvastatin
and of aspirin in patients with chronic renal impairment
Participants Patients on hemodialysis, chronic renal failure and transplanted patients
Interventions 1. The biochemical efficacy and safety of simvastatin (20mg daily), with assessment of efficacy from change
in serum lipid profile and of safety from markers of muscle and hepatic toxicity respectively; and
2. The safety of aspirin (100mgdaily) in terms of excess bleeding events, mean differences in haematological
parameters, and changes in renal function. A further objective is to assess the practibility of the planned
screening and follow-up procedures
Outcomes (i) SIMVASTATIN - efficacy: Mean differences in total-and LDL-cholesterol at 3 months and 12 months
after randomisation. Safety: differences in the incidence of CK> 10x upper limit of normal (ULN) and of
ALT> 2xULN. Mean differences in CK and ALT.
(ii) ASPIRIN - Safety: differences in the incidence of major bleeding episodes, and other bleeding episodes.
Differences in incidence of acute gout, and mean differences in serum urate. Mean differences in serum
creatinine. Differences in proportion with a doubling of serum creatinine or the need for renal replacement
therapy (predialysis only)
Starting date Start date: 29 March 1999
End date: 26 March 2004













Trial name or title Study of Heart and Renal protection (SHARP)
Methods
Participants The study will include about 9000 patients with Chronic Kidney Disease, of whom around 6000 are intended
to be pre-dialysis and 3000 on dialysis at randomisation
Interventions Simvastatin and ezetimibe versus placebo
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SHARP Study 2003 (Continued)
Outcomes Fatal and non-fatal Cardiac events, Fatal and non-fatal cerebrovascular events or revascularization
Starting date 17 November 2003
Contact information Dr Richard D’Souza
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D A T A A N D A N A L Y S E S
Comparison 1. HMG CoA reductase inhibitors (statins) versus placebo in dialysis patients




participants Statistical method Effect size
1 Total cholesterol (mg/dL) 5 357 Mean Difference (IV, Random, 95% CI) -53.74 [-66.95, -40.
54]
1.1 Peritoneal dialysis 3 164 Mean Difference (IV, Random, 95% CI) -64.16 [-86.81, -41.
51]
1.2 Hemodialysis 3 86 Mean Difference (IV, Random, 95% CI) -53.44 [-77.90, -28.
98]
1.3 Combined (PD and HD) 1 107 Mean Difference (IV, Random, 95% CI) -30.77 [-52.09, -9.
45]
2 LDL cholesterol (mg/dL) 5 357 Mean Difference (IV, Random, 95% CI) -55.40 [-69.90, -40.
90]
2.1 Peritoneal dialysis 3 164 Mean Difference (IV, Random, 95% CI) -76.44 [-106.12, -
46.77]
2.2 Hemodialysis 3 86 Mean Difference (IV, Random, 95% CI) -47.29 [-62.01, -32.
57]
2.3 Combined (PD and HD) 1 107 Mean Difference (IV, Random, 95% CI) -30.77 [-47.63, -13.
91]
3 HDL cholesterol (mg/dL) 5 357 Mean Difference (IV, Random, 95% CI) 2.19 [-0.30, 4.69]
3.1 Peritoneal dialysis 3 164 Mean Difference (IV, Random, 95% CI) -1.17 [-9.21, 6.87]
3.2 Hemodialysis 3 86 Mean Difference (IV, Random, 95% CI) 4.84 [0.28, 9.40]
3.3 Combined (PD and HD) 1 107 Mean Difference (IV, Random, 95% CI) 1.93 [-1.27, 5.13]
4 Triglycerides (mg/dL) 5 357 Mean Difference (IV, Random, 95% CI) -33.72 [-54.16, -13.
28]
4.1 Peritoneal dialysis 3 164 Mean Difference (IV, Random, 95% CI) -44.11 [-75.32, -12.
90]
4.2 Hemodialysis 3 86 Mean Difference (IV, Random, 95% CI) -32.48 [-66.73, 1.
76]
4.3 Combined (PD and HD) 1 107 Mean Difference (IV, Random, 95% CI) -15.01 [-59.12, 29.
12]
Comparison 2. HMG CoA reductase inhibitors (statins) versus other hypolidemic agents in dialysis patients




participants Statistical method Effect size
1 Total cholesterol (mg/dL) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
1.1 Peritoneal dialysis 0 Mean Difference (IV, Random, 95% CI) Not estimable
1.2 Hemodialysis 1 Mean Difference (IV, Random, 95% CI) -11.01 [-48.95, 26.
95]
2 LDL cholesterol (mg/dL) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Peritoneal dialysis 0 Mean Difference (IV, Random, 95% CI) Not estimable
20HMG CoA reductase inhibitors (statins) for dialysis patients (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2.2 Hemodialysis 1 Mean Difference (IV, Random, 95% CI) -20.01 [-51.87, 11.
87]
3 HDL cholesterol (mg/dL) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Peritoneal dialysis 0 Mean Difference (IV, Random, 95% CI) Not estimable
3.2 Hemodialysis 1 Mean Difference (IV, Random, 95% CI) 5.01 [-2.38, 12.38]
4 Triglycerides (mg/dL) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
4.1 Peritoneal dialysis 0 Mean Difference (IV, Random, 95% CI) Not estimable
4.2 Hemodialysis 1 Mean Difference (IV, Random, 95% CI) 91.00 [-5.26, 187.
26]
Comparison 3. Adverse event rates in dialysis patients




participants Statistical method Effect size
1 Withdrawal rate 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Peritoneal dialysis 2 199 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.07, 13.30]
1.2 Hemodilalysis 1 34 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.16, 4.24]
1.3 Combined (PD and HD) 1 107 Risk Ratio (M-H, Random, 95% CI) 1.53 [0.72, 3.22]
2 Elevated liver function test 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Peritoneal dialysis 2 200 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.16, 9.89]
2.2 Hemodialysis 1 34 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.11, 10.83]
2.3 Combined (PD and HD) 1 107 Risk Ratio (M-H, Random, 95% CI) Not estimable
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